Osteopontin Levels in Patients With Chronic Kidney Disease Stage 5 on Hemodialysis Directly Correlate With Intact Parathyroid Hormone and Alkaline Phosphatase

Druck, Aleksander; Patel, Dimpi; Bansal, Vinod; Hoppensteadt, Debra; Fareed, Jawed

doi:10.1177/1076029619896621

Cited by 9 publications

(6 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current study findings are consistent with previous studies in CKD showing elevated OPN serum levels mainly in the adult population with CKD (Druck et al, 2019;Barreto et al, 2011) [25] [26] some studies have related high circulating levels of OPN to adverse cardiovascular events in the general population (Waller et al, 2010) [23] and in CKD patients (Lamort et al, 2019) [27].…”

Section: Discussionsupporting

confidence: 93%

“…In addition, in the current study, we found a strong correlation between osteopontin and PTH. This is consistent with a recent study by (Druck et al, 2019) [25]. Indeed osteopontin may play an essential role in vascular calcification OPN knockout mice have been shown to have higher bone formation secondary to PTH-induced increase in osteoblast activity, and PTH infusion has been shown to increase OPN levels.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

The Relationship between Circulating Levels of Osteopontin with Carotid Intima-Media Thickness in Children on Regular Hemodialysis

Mohamed¹,

Tawfeek²,

Abdel-Salam³

et al. 2021

OJNeph

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 93%

The Relationship between Circulating Levels of Osteopontin with Carotid Intima-Media Thickness in Children on Regular Hemodialysis

Mohamed¹,

Tawfeek²,

Abdel-Salam³

et al. 2021

OJNeph

View full text Add to dashboard Cite

“…In a study of patients on maintenance hemodialysis, OPN levels were found to have significant positive correlations with intact parathyroid hormone, indicating that OPN may play an integral role in the mineral bone disorder axis. As such, the data suggest that it may be important to monitor OPN when managing patients on maintenance hemodialysis [124].…”

Section: End Stage Renal Disease (Esrd)mentioning

confidence: 99%

“…Knowledge of these approaches can potentially drive therapies targeting OPN and ntOPN in CKD (Figure 3). As such, the data suggest that it may be important to monitor OPN when managing patients on maintenance hemodialysis [124].…”

Section: Therapeutic Approaches To Modulate Opn Expression and Functionmentioning

confidence: 99%

Osteopontin as a Biomarker in Chronic Kidney Disease

et al. 2023

View full text Add to dashboard Cite

Osteopontin (OPN) is a ubiquitously expressed protein with a wide range of physiological functions, including roles in bone mineralization, immune regulation, and wound healing. OPN has been implicated in the pathogenesis of several forms of chronic kidney disease (CKD) where it promotes inflammation and fibrosis and regulates calcium and phosphate metabolism. OPN expression is increased in the kidneys, blood, and urine of patients with CKD, particularly in those with diabetic kidney disease and glomerulonephritis. The full-length OPN protein is cleaved by various proteases, including thrombin, matrix metalloproteinase (MMP)-3, MMP-7, cathepsin-D, and plasmin, producing N-terminal OPN (ntOPN), which may have more detrimental effects in CKD. Studies suggest that OPN may serve as a biomarker in CKD, and while more research is needed to fully evaluate and validate OPN and ntOPN as CKD biomarkers, the available evidence suggests that they are promising candidates for further investigation. Targeting OPN may be a potential treatment strategy. Several studies show that inhibition of OPN expression or activity can attenuate kidney injury and improve kidney function. In addition to its effects on kidney function, OPN has been linked to cardiovascular disease, which is a major cause of morbidity and mortality in patients with CKD.

show abstract

“…One study indicated that circulating levels of flOPN were closely related to GFR and CV risk markers in patients with CKD [42]. Elevated plasma flOPN was also reported in a cohort of patients with CKD stage 5 receiving hemodialysis (CKD 5-HD) compared to a normal healthy cohort [43]. Further, a significant positive correlation of flOPN with iPTH and alkaline phosphatase was observed in CKD 5-HD patients [43].…”

Section: Discussionmentioning

confidence: 99%

Vitamin D3 Repletion Improves Vascular Function, as Measured by Cardiorenal Biomarkers in a High-Risk African American Cohort

et al. 2022

View full text Add to dashboard Cite

Background: 25-hydroxy vitamin D (Vit D)-deficiency is common among patients with chronic kidney disease (CKD) and contributes to cardiovascular disease (CVD). African Americans (AAs) suffer disproportionately from CKD and CVD, and 80% of AAs are Vit D-deficient. The impact of Vit D repletion on cardio-renal biomarkers in AAs is unknown. We examined Vit D repletion on full-length osteopontin (flOPN), c-terminal fibroblast growth factor-23 (FGF-23), and plasminogen activator inhibitor-1 (PAI-1), which are implicated in vascular and kidney pathology. Methods: We performed a randomized, placebo-controlled study of high-risk AAs with Vit D deficiency, treated with 100,000 IU Vit D3 (cholecalciferol; n = 65) or placebo (n = 65) every 4 weeks for 12 weeks. We measured kidney function (CKD-EPI eGFR), protein-to-creatinine ratio, vascular function (pulse wave velocity; PWV), augmentation index, waist circumference, sitting, and 24-h-ambulatory blood pressure (BP), intact parathyroid hormone (iPTH) and serum calcium at baseline and study end, and compared Vit D levels with laboratory variables. We quantified plasma FGF-23, PAI-1, and flOPN by enzyme-linked immunosorbent assay. Multiple regression analyzed the relationship between log flOPN, FGF-23, and PAI-1 with vascular and renal risk factors. Results: Compared to placebo, Vit D3 repletion increased Vit D3 2-fold (p < 0.0001), decreased iPTH by 12% (p < 0.01) and was significantly correlated with PWV (p < 0.009). Log flOPN decreased (p = 0.03), log FGF-23 increased (p = 0.04), but log PAI-1 did not change. Multiple regression indicated association between log flOPN and PWV (p = 0.04) and diastolic BP (p = 0.02), while log FGF-23 was associated with diastolic BP (p = 0.05), and a trend with eGFR (p = 0.06). Conclusion: Vit D3 repletion may reduce flOPN and improve vascular function in high risk AAs with Vit D deficiency.

show abstract

Osteopontin Levels in Patients With Chronic Kidney Disease Stage 5 on Hemodialysis Directly Correlate With Intact Parathyroid Hormone and Alkaline Phosphatase

Cited by 9 publications

References 39 publications

The Relationship between Circulating Levels of Osteopontin with Carotid Intima-Media Thickness in Children on Regular Hemodialysis

The Relationship between Circulating Levels of Osteopontin with Carotid Intima-Media Thickness in Children on Regular Hemodialysis

Osteopontin as a Biomarker in Chronic Kidney Disease

Vitamin D3 Repletion Improves Vascular Function, as Measured by Cardiorenal Biomarkers in a High-Risk African American Cohort

Contact Info

Product

Resources

About